Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 1.1% – What’s Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price was up 1.1% during mid-day trading on Friday . The stock traded as high as $10.40 and last traded at $9.78. Approximately 220,419 shares were traded during trading, a decline of 84% from the average daily volume of 1,377,421 shares. The stock had previously closed at $9.67.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a report on Monday, February 10th. They issued a “sell” rating for the company.

Tonix Pharmaceuticals Price Performance

The stock has a market capitalization of $17.14 million, a P/E ratio of 0.00 and a beta of 2.07. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The business’s 50 day simple moving average is $27.92 and its two-hundred day simple moving average is $23.27.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in shares of Tonix Pharmaceuticals by 1,600.1% in the 4th quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock worth $650,000 after purchasing an additional 1,855,907 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Tonix Pharmaceuticals by 5,932.3% in the 4th quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock worth $548,000 after acquiring an additional 1,635,119 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Tonix Pharmaceuticals in the 4th quarter valued at $526,000. Northern Trust Corp bought a new position in shares of Tonix Pharmaceuticals during the 4th quarter valued at $162,000. Finally, PFG Investments LLC purchased a new stake in Tonix Pharmaceuticals during the fourth quarter valued at about $72,000. Institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.